Chondrosarcoma - Pipeline Insight, 2024

This “Chondrosarcoma- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Chondrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chondrosarcoma: Understanding

Chondrosarcoma: Overview

Chondrosarcoma (CS), is a group of bone tumors that are made up of cells that make too much cartilage. Cartilage is the specialized, gristly connective tissue that is present in adults and the tissue from which most bones develop. Cartilage plays an important role in the growth process. There are many different types of cartilage that are present throughout the body. Chondrosarcoma primarily affects the cartilage cells of the femur (thighbone), arm, pelvis, or knee. Although less often, other areas (such as the ribs) may be affected. Chondrosarcomas are malignant cartilaginous neoplasms with diverse morphological features and clinical behavior. They account for about 20% of all primary malignant tumors of the bone. They usually arise in the pelvis or long bones. Primary or conventional chondrosarcoma arises in preexisting normal bone and is distinguished from the rarer secondary tumors, which occur in a preexisting enchondroma or osteochondroma. Conventional chondrosarcoma, which accounts for 85%-90% of chondrosarcomas is subdivided into the central, periosteal, and peripheral subgroups. Non-conventional chondrosarcoma variants include clear cell chondrosarcoma, mesenchymal chondrosarcoma, and dedifferentiated chondrosarcoma. The radiographic features of chondrosarcoma are often very characteristic, and a definitive diagnosis can usually be made by imaging examination alone. Chondrosarcoma tends to grow slowly, so it might not cause signs and symptoms at first. The most common locations of involvement of chondrosarcoma include the bones of the axial skeleton (pelvis, scapula, sternum, and ribs) followed by the proximal femur and proximal humerus. Involvement of the hands and feet is rare. A risk factor is anything that may increase your chance of having a disease. The exact cause of someone’s cancer may not be known. But risk factors can make it more likely for a person to have cancer. Imaging studies - including radiographs (x-rays), computerized tomography (CT), and magnetic resonance imaging (MRI) - are often used to make a presumptive diagnosis of chondrosarcoma. However, a definitive diagnosis depends on the identification of malignant cancer cells producing cartilage in a biopsy specimen that has been examined by a pathologist. In a few cases, usually of highly anaplastic tumors, immunohistochemistry (IHC) is required. The treatment depends on the size of the tumor, where it is, and its grade. It will also depend on the symptoms, age, general health, and preferences. The goal for treatment of chondrosarcoma is to remove the tumor and reduce the chance that it will return.

Chondrosarcoma- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chondrosarcoma pipeline landscape is provided which includes the disease overview and Chondrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Chondrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Chondrosarcoma.

Chondrosarcoma Emerging Drugs Chapters

This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chondrosarcoma Emerging Drugs

Trabectedin: Pharma Mar Trabectedin, also known as ecteinascidin 743 or ET-743l, or commercially where it is approved as Yondelis® is a synthetic compound derived from the colonial sea squirt Ecteinascidia turbinata. Trabectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis. Trabectedin (Yondelis) is an anti-tumor agent of marine origin discovered in the caribbean tunicate, ecteinascidia turbinata. It is formulated as lyophilized powder for solution for injection for intravenous route of administration. Yondelis is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of MesenchymalChondrosarcoma.

INBRX-109: Inhibrx INBRX-109 is a precisely engineered tetravalent single domain antibody (sdAb)-based therapeutic candidate that agonizes death receptor 5 (DR5) to induce tumor selective programmed cell death. INBRX-109, is a tetravalent DR5 agonistic antibody, designed to exploit tumor-biased direct cell death induction by DR5 activation in numerous cancer types. With a valency of four, it has the ability to potently agonize DR5 through efficient receptor clustering, causing cell death, but by way of the sdAb platform, also eliminates recognition by pre-existing anti-drug antibodies (ADAs) to lessen the potential for hyper-clustering. In preclinical studies, INBRX-109 led to antitumor activity in vitro and in patient-derived xenograft models, with minimal hepatotoxicity. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment ofChondrosarcoma.

JS001sc: Shanghai Junshi Bioscience Co., Ltd.JS001sc injection is a subcutaneous injection formulation developed by Junshi Biosciences on the basis of the marketed product toripalimab. JS001sc targets PD-1, binds to PD-1 with high affinity, and selectively blocks the binding of PD-1 to the ligands PD-L1 and PD-L2, thereby activating T lymphocytes and improving lymphocyte proliferation and cytokine secretion. The pre-clinical in vivo pharmacodynamics shows that JS001sc exhibits significant anti-tumor effect in animal models by subcutaneous injection. At certain dose level, the anti-tumor effect of JS001sc administered by subcutaneous injection is comparable to that of toripalimab administered by intravenous injection, with no significant difference. In addition, animals have a good tolerance to JS001sc. So far, JS001sc has received the clinical trial approval from the NMPA. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chondrosarcoma.

HMPL-306: Hutchmed HMPL-306, is an investigational drug being developed by Hutchmed. HMPL-306 is an investigational novel selective small molecule dual inhibitor of isocitrate dehydrogenase (IDH) 1 and 2 mutations. IDH1 and IDH2 mutations have been implicated as drivers of certain hematological malignancies, gliomas and solid tumors, particularly among acute myeloid leukemia patients. Cytoplasmic mutant IDH1 and mitochondrial mutant IDH2 have been known to switch to the other form when targeted by an inhibitor of IDH1 mutant alone or IDH2 mutant alone. Cancer patients harboring either IDH mutation have been known to develop resistance to therapies that target IDH1 or IDH2 through isoform switching. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment ofChondrosarcoma.

Chondrosarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chondrosarcoma

There are approx. 15+ key companies which are developing the therapies for Chondrosarcoma. The companies which have their Chondrosarcoma drug candidates in the most advanced stage, i.e. phase II include, Pharma Mar.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chondrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chondrosarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.

Chondrosarcoma Report Insights

• Chondrosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chondrosarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chondrosarcoma drugs?
• How many Chondrosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chondrosarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chondrosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pharma Mar
• Inhibrx
• Shanghai Junshi Bioscience Co., Ltd.
• Hutchmed
• Atlanthera

Key Products

• Trabectedin
• INBRX-109
• JS-001sc
• HMPL-306
• Ifosfamide

This product will be delivered within 1-3 business days.